documents
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
287 rows where agency_id = "DEA" and document_type = "Rule" sorted by posted_date descending
This data as json, CSV (advanced)
Suggested facets: posted_date (date), comment_start_date (date), last_modified (date)
| id | agency_id | docket_id | title | document_type | subtype | posted_date ▲ | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DEA_FRDOC_0001-0508 | DEA | Recently Posted DEA Rules and Notices DEA_FRDOC_0001 | Designation of Propionyl Chloride as a List I Chemical | Rule | 2026-03-10T04:00:00Z | 2026 | 3 | 2026-03-10T04:00:00Z | 2026-03-10T16:55:22Z | 2026-04657 | 0 | 0 | 09000064b9206be3 | ||
| DEA_FRDOC_0001-0507 | DEA | Recently Posted DEA Rules and Notices DEA_FRDOC_0001 | Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act | Rule | 2026-03-02T05:00:00Z | 2026 | 3 | 2026-03-02T05:00:00Z | 2026-03-02T18:40:50Z | 2026-04112 | 0 | 0 | 09000064b91e8fdf | ||
| DEA_FRDOC_0001-0506 | DEA | Recently Posted DEA Rules and Notices DEA_FRDOC_0001 | Registering Emergency Medical Services Agencies under the Protecting Patient Access to Emergency Medications Act of 2017 | Rule | 2026-02-05T05:00:00Z | 2026 | 2 | 2026-02-05T05:00:00Z | 2026-02-05T17:30:25Z | 2026-02288 | 0 | 0 | 09000064b919298b | ||
| DEA-2023-0057-0003 | DEA | Definition of ‘‘Cannabimimetic Agents’’ and Assignment of an Administration Controlled Substances Code Number for All ‘‘Cannabimimetic Agents’’ (DEA368) DEA-2023-0057 | Definition of Cannabimimetic Agents and Assignment of an Administration Controlled Substances Code Number for all Cannabimimetic Agents | Rule | 2026-01-20T05:00:00Z | 2026 | 1 | 2026-01-20T05:00:00Z | 2026-01-20T23:44:45Z | 2026-00907 | 0 | 0 | 09000064b9161314 | ||
| DEA-2025-0075-0014 | DEA | Placement of 4-Fluoroamphetamine in Schedule I (DEA1180) DEA-2025-0075 | Schedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule I | Rule | 2026-01-15T05:00:00Z | 2026 | 1 | 2026-01-15T05:00:00Z | 2026-01-16T20:17:00Z | 2026-00633 | 0 | 0 | 09000064b9152a07 | ||
| DEA-2024-0118-0004 | DEA | Schedules of Controlled Substances: Temporary Placement of N-Pyrrolidino Metonitazene and N-Pyrrolidino Protonitazene in Schedule I (DEA1337) DEA-2024-0118 | Schedules of Controlled Substances: Placement of N-Pyrrolidino Metonitazene and N-Pyrrolidino Protonitazene in Schedule I | Rule | 2026-01-12T05:00:00Z | 2026 | 1 | 2026-01-12T05:00:00Z | 2026-01-13T02:58:59Z | 2026-00362 | 0 | 0 | 09000064b913658f | ||
| DEA-2023-0029-41937 | DEA | Telemedicine Prescribing of Controlled Substances (DEA407) DEA-2023-0029 | Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications | Rule | 2025-12-31T05:00:00Z | 2025 | 12 | 2025-12-31T05:00:00Z | 2026-01-13T03:01:01Z | 2025-24123 | 0 | 0 | 09000064b9113f32 | ||
| DEA-2023-0147-0004 | DEA | Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I (DEA1143) DEA-2023-0147 | Schedules of Controlled Substances: Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I | Rule | 2025-12-23T05:00:00Z | 2025 | 12 | 2025-12-23T05:00:00Z | 2026-01-06T01:10:17Z | 2025-23717 | 0 | 0 | 09000064b91067de | ||
| DEA-2025-0918-0001 | DEA | Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I of the Controlled Substances Act (DEA1604) DEA-2025-0918 | Schedules of Controlled Substances: Extension of Temporary Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I of the Controlled Substances Act | Rule | 2025-12-16T05:00:00Z | 2025 | 12 | 2025-12-16T05:00:00Z | 2025-12-16T21:28:16Z | 2025-22960 | 0 | 0 | 09000064b90da7df | ||
| DEA-2025-0555-0055 | DEA | Schedules of Controlled Substances: Placement of MDMB-4-PINACA in Schedule I (DEA1356) DEA-2025-0555 | Schedules of Controlled Substances: Extension of Temporary Placement of MDMB-4en-PINACA in Schedule I | Rule | 2025-12-11T05:00:00Z | 2025 | 12 | 2025-12-11T05:00:00Z | 2025-12-11T19:41:46Z | 2025-22540 | 0 | 0 | 09000064b90c55b5 | ||
| DEA-2025-0852-0002 | DEA | Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I (DEA1511) DEA-2025-0852 | Schedules of Controlled Substances: Extension of Temporary Placement of CUMYL-PEGACLONE in Schedule I | Rule | 2025-12-11T05:00:00Z | 2025 | 12 | 2025-12-11T05:00:00Z | 2025-12-11T19:46:09Z | 2025-22496 | 0 | 0 | 09000064b90c55b7 | ||
| DEA-2024-0144-0006 | DEA | Schedules of Controlled Substances: Placement of 4-Chloromethcathinone in Schedule I (DEA1246) DEA-2024-0144 | Schedules of Controlled Substances: Placement of 4-Chloromethcathinone in Schedule I | Rule | 2025-11-17T05:00:00Z | 2025 | 11 | 2025-11-17T05:00:00Z | 2025-11-20T02:13:12Z | 2025-20004 | 0 | 0 | 09000064b9085a3d | ||
| DEA-2025-0588-0001 | DEA | Schedules of Controlled Substances: Temporary Placement of ethyleneoxynitazene, methylenedioxynitazene, 5-methyl etodesnitazene, N-desethyl etonitazene, N-desethyl protonitazene, N,N-dimethylamino etonitazene, and N-pyrrolidino isotonitazene in Schedule I (DEA1494) DEA-2025-0588 | Schedules of Controlled Substances: Temporary Placement of ethyleneoxynitazene, methylenedioxynitazene, 5-methyl etodesnitazene, N-desethyl etonitazene, N-desethyl protonitazene, N,N-dimethylamino etonitazene, and N-pyrrolidino isotonitazene in Schedule I | Rule | 2025-10-15T04:00:00Z | 2025 | 10 | 2025-10-15T04:00:00Z | 2025-10-17T03:23:35Z | 2025-19542 | 0 | 0 | 09000064b901aa49 | ||
| DEA-2025-0558-0001 | DEA | Requiring Online Submission of Applications for and Renewals of DEA Registration; Correction (DEA1111) DEA-2025-0558 | Requiring Online Submission of Applications for and Renewals of DEA Registration; Correction | Rule | 2025-10-02T04:00:00Z | 2025 | 10 | 2025-10-02T04:00:00Z | 2025-10-03T01:30:04Z | 2025-19292 | 0 | 0 | 09000064b8ff064c | ||
| DEA-2023-0016-0010 | DEA | Controlled Substances Ordering System Modernization (DEA732) DEA-2023-0016 | Controlled Substances Ordering System Modernization | Rule | 2025-10-02T04:00:00Z | 2025 | 10 | 2025-10-02T04:00:00Z | 2025-10-03T01:31:47Z | 2025-19325 | 0 | 0 | 09000064b8ff074c | ||
| DEA-2025-0556-0001 | DEA | Specific Listing for 1-boc-4-piperidone, a Currently Controlled List I Chemical DEA-2025-0556 | Specific Listing for 1-boc-4-piperidone, a Currently Controlled List I Chemical | Rule | 2025-10-02T04:00:00Z | 2025 | 10 | 2025-10-02T04:00:00Z | 2025-10-03T01:20:48Z | 2025-19349 | 0 | 0 | 09000064b8ff07c5 | ||
| DEA-2024-0148-0006 | DEA | Schedules of Controlled Substances: Placement of Seven Specific Fentanyl-Related Substances in Schedule I of the Controlled Substances Act (DEA1457) DEA-2024-0148 | Schedules of Controlled Substances: Placement of Seven Specific Fentanyl-Related Substances in Schedule I | Rule | 2025-09-18T04:00:00Z | 2025 | 9 | 2025-09-18T04:00:00Z | 2025-10-03T01:28:48Z | 2025-18103 | 0 | 0 | 09000064b8fb0ed1 | ||
| DEA-2024-0118-0003 | DEA | Schedules of Controlled Substances: Temporary Placement of N-Pyrrolidino Metonitazene and N-Pyrrolidino Protonitazene in Schedule I (DEA1337) DEA-2024-0118 | Schedules of Controlled Substances: Temporary Placement of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I | Rule | 2025-08-15T04:00:00Z | 2025 | 8 | 2025-08-15T04:00:00Z | 2025-08-15T17:55:48Z | 2025-15566 | 0 | 0 | 09000064b8f008ec | ||
| DEA-2025-0192-0003 | DEA | Specific Listing for Dipentylone, a Currently Controlled Schedule I Substance (DEA1390) DEA-2025-0192 | Specific Listing for Dipentylone, A Currently Controlled Schedule I Substance | Rule | 2025-08-08T04:00:00Z | 2025 | 8 | 2025-08-08T04:00:00Z | 2025-09-10T04:16:28Z | 2025-15177 | 0 | 0 | 09000064b8ef0c9b | ||
| DEA-2022-0145-0005 | DEA | Schedules of Controlled Substances: Temporary Placement of Etizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I (DEA989) DEA-2022-0145 | Schedules of Controlled Substances: Extension of Temporary Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I | Rule | 2025-07-25T04:00:00Z | 2025 | 7 | 2025-07-25T04:00:00Z | 2025-07-25T16:18:35Z | 2025-14037 | 0 | 0 | 09000064b8e9cab5 | ||
| DEA-2024-0026-0002 | DEA | Placement of 2-Methyl AP-237 in Schedule I (DEA1245) DEA-2024-0026 | Schedules of Controlled Substances: Placement of 2-Methyl AP-237 in Schedule I; Correction | Rule | 2025-06-03T00:00:00Z | 2025 | 6 | 2025-06-03T00:00:00Z | 2025-06-03T21:07:54Z | 2025-09989 | 0 | 0 | 09000064b8dceccb | ||
| DEA-2023-0028-2951 | DEA | Expansion of Induction of Buprenorphine via Telemedicine Encounter (DEA948) DEA-2023-0028 | Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients | Rule | 2025-03-24T04:00:00Z | 2025 | 3 | 2025-03-24T04:00:00Z | 2025-06-03T00:09:09Z | 2025-05007 | 0 | 0 | 0900006486a29032 | ||
| DEA-2023-0028-2918 | DEA | Expansion of Induction of Buprenorphine via Telemedicine Encounter (DEA948) DEA-2023-0028 | Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients | Rule | 2025-02-19T05:00:00Z | 2025 | 2 | 2025-02-19T05:00:00Z | 2025-03-01T04:59:59Z | 2025-03-01T23:55:45Z | 2025-02793 | 0 | 0 | 0900006486971375 | |
| DEA-2023-0028-2917 | DEA | Expansion of Induction of Buprenorphine via Telemedicine Encounter (DEA948) DEA-2023-0028 | Expansion of Buprenorphine Treatment via Telemedicine Encounter | Rule | 2025-01-17T05:00:00Z | 2025 | 1 | 2025-01-17T05:00:00Z | 2025-01-21T13:53:50Z | 2025-01049 | 0 | 0 | 09000064868e2eb2 | ||
| DEA-2023-0029-35464 | DEA | Telemedicine Prescribing of Controlled Substances (DEA407) DEA-2023-0029 | Continuity of Care via Telemedicine for Veterans Affairs Patients | Rule | 2025-01-17T05:00:00Z | 2025 | 1 | 2025-01-17T05:00:00Z | 2025-01-21T13:54:28Z | 2025-01044 | 0 | 0 | 09000064868e2ffd | ||
| DEA-2024-0148-0001 | DEA | Schedules of Controlled Substances: Placement of Seven Specific Fentanyl-Related Substances in Schedule I of the Controlled Substances Act (DEA1457) DEA-2024-0148 | Schedules of Controlled Substances: Extension of Temporary Placement of Seven Specific Fentanyl-Related Substances in Schedule I | Rule | 2024-12-30T05:00:00Z | 2024 | 12 | 2024-12-30T05:00:00Z | 2024-12-30T17:26:55Z | 2024-31130 | 0 | 0 | 09000064868950c5 | ||
| DEA-2023-0029-35463 | DEA | Telemedicine Prescribing of Controlled Substances (DEA407) DEA-2023-0029 | Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications | Rule | 2024-11-19T05:00:00Z | 2024 | 11 | 2024-11-19T05:00:00Z | 2024-11-27T19:50:54Z | 2024-27018 | 0 | 0 | 090000648682777c | ||
| DEA-2021-0031-0011 | DEA | Schedules of Controlled Substances: Temporary Placement of Butonitazene, Etodesnitazene, Flunitazene, Metodesnitazene, Metonitazene, N-pyrrolidino etonitazene, and Protonitazene in Schedule I DEA-2021-0031 | Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene in Schedule I | Rule | 2024-10-25T04:00:00Z | 2024 | 10 | 2024-10-25T04:00:00Z | 2024-10-25T18:56:31Z | 2024-24635 | 0 | 0 | 09000064867e36b5 | ||
| DEA-2023-0129-0013 | DEA | Placement of Ethylphenidate in Schedule I (DEA1142) DEA-2023-0129 | Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I | Rule | 2024-10-22T04:00:00Z | 2024 | 10 | 2024-10-22T04:00:00Z | 2024-10-24T14:27:34Z | 2024-24083 | 0 | 0 | 09000064867dd715 | ||
| DEA-2023-0149-0005 | DEA | Placement of Zuranolone in Schedule IV (DEA1258) DEA-2023-0149 | Schedules of Controlled Substances: Placement of Zuranolone in Schedule IV | Rule | 2024-08-14T04:00:00Z | 2024 | 8 | 2024-08-14T04:00:00Z | 2024-09-03T22:47:05Z | 2024-18087 | 0 | 0 | 0900006486643896 | ||
| DEA-2023-0147-0003 | DEA | Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I (DEA1143) DEA-2023-0147 | Schedules of Controlled Substances: Temporary Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I | Rule | 2024-07-29T04:00:00Z | 2024 | 7 | 2024-07-29T04:00:00Z | 2024-09-03T22:44:11Z | 2024-16391 | 0 | 0 | 090000648660a036 | ||
| DEA-2021-0031-0006 | DEA | Schedules of Controlled Substances: Temporary Placement of Butonitazene, Etodesnitazene, Flunitazene, Metodesnitazene, Metonitazene, N-pyrrolidino etonitazene, and Protonitazene in Schedule I DEA-2021-0031 | Schedules of Controlled Substances: Placement of Etodesnitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I | Rule | 2024-04-11T04:00:00Z | 2024 | 4 | 2024-04-11T04:00:00Z | 2024-05-03T19:53:46Z | 2024-07684 | 0 | 0 | 09000064864cd87a | ||
| DEA-2021-0031-0008 | DEA | Schedules of Controlled Substances: Temporary Placement of Butonitazene, Etodesnitazene, Flunitazene, Metodesnitazene, Metonitazene, N-pyrrolidino etonitazene, and Protonitazene in Schedule I DEA-2021-0031 | Schedules of Controlled Substances: Extension of Temporary Placement of Butonitazene, Flunitazene, and Metodesnitazene in Schedule I of the Controlled Substances Act | Rule | 2024-04-11T04:00:00Z | 2024 | 4 | 2024-04-11T04:00:00Z | 2024-05-03T19:54:53Z | 2024-07689 | 0 | 0 | 09000064864cd9c1 | ||
| DEA-2024-0026-0001 | DEA | Placement of 2-Methyl AP-237 in Schedule I (DEA1245) DEA-2024-0026 | Schedules of Controlled Substances: Placement of 2-Methyl AP-237 in Schedule I | Rule | 2024-03-15T04:00:00Z | 2024 | 3 | 2024-03-15T04:00:00Z | 2024-03-19T12:47:48Z | 2024-05543 | 0 | 0 | 090000648647c8be | ||
| DEA-2024-0009-0001 | DEA | Conforming Amendment Regarding the Veterinary Medicine Mobility Act of 2014 DEA-2024-0009 | Conforming Amendment Regarding the Veterinary Medicine Mobility Act of 2014 | Rule | 2024-02-08T05:00:00Z | 2024 | 2 | 2024-02-08T05:00:00Z | 2024-02-08T15:01:26Z | 2024-02322 | 0 | 0 | 09000064863f3b32 | ||
| DEA-2023-0169-0001 | DEA | Specific Listing for Three Currently Controlled Schedule I Substances (DEA1222) DEA-2023-0169 | Specific Listing for Currently Controlled Schedule I Substances | Rule | 2023-12-13T05:00:00Z | 2023 | 12 | 2023-12-13T05:00:00Z | 2023-12-13T13:32:21Z | 2023-27292 | 0 | 0 | 09000064863313c0 | ||
| DEA-2023-0049-0004 | DEA | Temporary Placement of MDMB-4en-PINACA, 4F-MDMB-BUTICA, ADB-4en-PINACA, CUMYL-PEGACLONE, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I (DEA1006) DEA-2023-0049 | Schedules of Controlled Substances: Temporary Placement of MDMB–4en–PINACA, 4F–MDMB–BUTICA, ADB–4en–PINACA, CUMYL–PEGACLONE, 5F–EDMB–PICA, and MMB–FUBICA into Schedule I | Rule | 2023-12-12T05:00:00Z | 2023 | 12 | 2023-12-12T05:00:00Z | 2023-12-12T15:08:02Z | 2023-27243 | 0 | 0 | 0900006486328332 | ||
| DEA-2023-0058-0012 | DEA | Placement of Nine Specific Fentanyl Related Substances in Schedule I (DEA1036) DEA-2023-0058 | Schedules of Controlled Substances: Placement of Nine Specific Fentanyl-Related Substances in Schedule I | Rule | 2023-12-07T05:00:00Z | 2023 | 12 | 2023-12-07T05:00:00Z | 2023-12-07T13:20:25Z | 2023-26694 | 0 | 0 | 090000648630ac74 | ||
| DEA-2023-0059-0002 | DEA | Designation as List I Chemicals: Halides of 4-Anilinopiperidine (DEA1098) DEA-2023-0059 | Designation of Halides of 4-Anilinopiperidine as List I Chemicals | Rule | 2023-10-31T04:00:00Z | 2023 | 10 | 2023-10-31T04:00:00Z | 2023-10-31T13:33:44Z | 2023-23927 | 0 | 0 | 090000648619fb8c | ||
| DEA-2023-0149-0001 | DEA | Placement of Zuranolone in Schedule IV (DEA1258) DEA-2023-0149 | Schedules of Controlled Substances: Placement of Zuranolone in Schedule IV | Rule | 2023-10-31T04:00:00Z | 2023 | 10 | 2023-10-31T04:00:00Z | 2023-12-01T04:59:59Z | 2023-11-16T02:00:24Z | 2023-23982 | 0 | 0 | 090000648619fc3f | |
| DEA-2023-0146-0001 | DEA | Additions to Listing of Exempt Chemical Mixtures (DEA1118) DEA-2023-0146 | Additions to Listing of Exempt Chemical Mixtures | Rule | 2023-10-23T04:00:00Z | 2023 | 10 | 2023-10-23T04:00:00Z | 2023-11-23T04:59:59Z | 2023-10-24T00:51:02Z | 2023-23315 | 0 | 0 | 090000648612376e | |
| DEA-2023-0029-35462 | DEA | Telemedicine Prescribing of Controlled Substances (DEA407) DEA-2023-0029 | Second Temporary Extension of COVID–19 Telemedicine Flexibilities for Prescription of Controlled Medications | Rule | 2023-10-10T04:00:00Z | 2023 | 10 | 2023-10-10T04:00:00Z | 2023-10-11T12:17:00Z | 2023-22406 | 0 | 0 | 0900006486098b08 | ||
| DEA-2019-0013-0260 | DEA | Management of Quotas for Controlled Substances and List I Chemicals DEA-2019-0013 | Management of Quotas for Controlled Substances and List I Chemicals | Rule | 2023-08-31T04:00:00Z | 2023 | 8 | 2023-08-31T04:00:00Z | 2023-08-31T12:33:18Z | 2023-18885 | 0 | 0 | 0900006485f1e8bc | ||
| DEA-2021-0031-0005 | DEA | Schedules of Controlled Substances: Temporary Placement of Butonitazene, Etodesnitazene, Flunitazene, Metodesnitazene, Metonitazene, N-pyrrolidino etonitazene, and Protonitazene in Schedule I DEA-2021-0031 | Schedules of Controlled Substances: Placement of Metonitazene in Schedule I | Rule | 2023-08-18T04:00:00Z | 2023 | 8 | 2023-08-18T04:00:00Z | 2023-08-18T12:43:23Z | 2023-17778 | 0 | 0 | 0900006485e84a8b | ||
| DEA-2023-0106-0001 | DEA | Dispensing of Narcotic Drugs to Relieve Acute Withdrawal Symptoms of Opioid Use Disorder (DEA702) DEA-2023-0106 | Dispensing of Narcotic Drugs to Relieve Acute Withdrawal Symptoms of Opioid Use Disorder | Rule | 2023-08-08T04:00:00Z | 2023 | 8 | 2023-08-08T04:00:00Z | 2023-08-18T12:40:11Z | 2023-16892 | 0 | 0 | 0900006485dfb7fe | ||
| DEA-2023-0098-0001 | DEA | Implementation of the Designer Anabolic Steroid Control Act of 2014 (DEA481) DEA-2023-0098 | Implementation of the Designer Anabolic Steroid Control Act | Rule | 2023-08-01T04:00:00Z | 2023 | 8 | 2023-08-01T04:00:00Z | 2023-08-01T13:29:53Z | 2023-15747 | 0 | 0 | 0900006485d9b704 | ||
| DEA-2021-0026-0185 | DEA | Transfer of Electronic Prescriptions for Controlled Substances for Initial Filling DEA-2021-0026 | Initial Filling: Transfer of Electronic Prescriptions for Schedules II–V Controlled Substances between Pharmacies | Rule | 2023-07-27T04:00:00Z | 2023 | 7 | 2023-07-27T04:00:00Z | 2023-07-27T21:35:24Z | 2023-15847 | 0 | 0 | 0900006485d5e100 | ||
| DEA-2022-0145-0004 | DEA | Schedules of Controlled Substances: Temporary Placement of Etizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I (DEA989) DEA-2022-0145 | Schedules of Controlled Substances: Temporary Placement ofEtizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I | Rule | 2023-07-26T04:00:00Z | 2023 | 7 | 2023-07-26T04:00:00Z | 2025-07-30T17:42:01Z | 2023-15748 | 0 | 0 | 0900006485d4c9a5 | ||
| DEA-2020-0035-0039 | DEA | Partial Filling of Prescriptions for Schedule II Controlled Substances DEA-2020-0035 | Partial Filling of Prescriptions for Schedule II Controlled Substances | Rule | 2023-07-21T04:00:00Z | 2023 | 7 | 2023-07-21T04:00:00Z | 2023-07-21T12:48:18Z | 2023-15508 | 0 | 0 | 0900006485cf8fba | ||
| DEA-2020-0038-0006 | DEA | Schedules of Controlled Substances: Placement of Brorphine in Schedule I DEA-2020-0038 | Schedules of Controlled Substances: Placement of Brorphine in Schedule I; Correction | Rule | 2023-07-19T04:00:00Z | 2023 | 7 | 2023-07-19T04:00:00Z | 2023-07-19T15:15:05Z | 2023-15249 | 0 | 0 | 0900006485cdb926 | ||
| DEA-2020-0022-0024 | DEA | Reporting of Theft or Significant Loss of Controlled Substances DEA-2020-0022 | Reporting Theft or Significant Loss of Controlled Substances | Rule | 2023-06-22T04:00:00Z | 2023 | 6 | 2023-06-22T04:00:00Z | 2023-06-22T15:34:58Z | 2023-13085 | 0 | 0 | 0900006485bb0971 | ||
| DEA-2023-0029-35460 | DEA | Telemedicine Prescribing of Controlled Substances (DEA407) DEA-2023-0029 | Temporary Extension of COVID–19 Telemedicine Flexibilities for Prescription of Controlled Medications | Rule | 2023-05-10T04:00:00Z | 2023 | 5 | 2023-05-10T04:00:00Z | 2023-05-10T13:01:17Z | 2023-09936 | 0 | 0 | 09000064859ed53c | ||
| DEA-2022-0102-0005 | DEA | Designation of 4-Piperidone as a List I Chemical (DEA951) DEA-2022-0102 | Designation of a List I Chemical: 4-Piperidone | Rule | 2023-04-12T04:00:00Z | 2023 | 4 | 2023-04-12T04:00:00Z | 2023-04-12T12:28:23Z | 2023-07538 | 0 | 0 | 090000648593437e | ||
| DEA-2023-0056-0001 | DEA | Specific Listing for Eutylone, a Currently Controlled Schedule I Substance (DEA1003) DEA-2023-0056 | Specific Listing for Eutylone, a Currently Controlled Schedule I Substance | Rule | 2023-04-10T04:00:00Z | 2023 | 4 | 2023-04-10T04:00:00Z | 2023-04-10T14:31:00Z | 2023-07335 | 0 | 0 | 090000648591b81a | ||
| DEA-2020-0038-0005 | DEA | Schedules of Controlled Substances: Placement of Brorphine in Schedule I DEA-2020-0038 | Schedules of Controlled Substances: Placement of Brorphine in Schedule I | Rule | 2023-03-06T05:00:00Z | 2023 | 3 | 2023-03-06T05:00:00Z | 2023-03-07T14:27:36Z | 2023-04364 | 0 | 0 | 09000064857608c9 | ||
| DEA-2022-0068-0003 | DEA | Schedules of Controlled Substances: Removal of Fenfluramine From Control DEA-2022-0068 | Schedules of Controlled Substances: Removal of Fenfluramine from Control | Rule | 2022-12-23T05:00:00Z | 2022 | 12 | 2022-12-23T05:00:00Z | 2022-12-23T13:05:30Z | 2022-27400 | 0 | 0 | 0900006485550c29 | ||
| DEA-2021-0013-0006 | DEA | Schedules of Controlled Substances: Placement of Methiopropamine in Schedule I DEA-2021-0013 | Schedules of Controlled Substances: Placement of Methiopropamine in Schedule I | Rule | 2022-12-09T05:00:00Z | 2022 | 12 | 2022-12-09T05:00:00Z | 2022-12-12T14:18:13Z | 2022-26805 | 0 | 0 | 090000648552a6b4 | ||
| DEA-2022-0137-0001 | DEA | Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2023 DEA-2022-0137 | 2023 Established APQ | Rule | 2022-12-02T05:00:00Z | 2022 | 12 | 2022-12-02T05:00:00Z | 2022-12-02T14:49:04Z | 0 | 0 | 09000064855122e6 | |||
| DEA-2020-0027-0007 | DEA | Default Provisions for Hearing Proceedings Relating to the Revocation, Suspension, or Denial of a Registration DEA-2020-0027 | Default Provisions for Hearing Proceedings Relating to the Revocation, Suspension, or Denial of a Registration; Correction | Rule | 2022-11-29T05:00:00Z | 2022 | 11 | 2022-11-29T05:00:00Z | 2022-11-30T13:07:10Z | 2022-25823 | 0 | 0 | 0900006485507c87 | ||
| DEA-2021-0012-0004 | DEA | Schedules of Controlled Substances: Placement of Mesocarb in Schedule I DEA-2021-0012 | Schedules of Controlled Substances: Placement of Mesocarb in Schedule I | Rule | 2022-11-22T05:00:00Z | 2022 | 11 | 2022-11-22T05:00:00Z | 2022-11-22T13:27:04Z | 2022-25219 | 0 | 0 | 09000064854fbb4f | ||
| DEA-2021-0025-0010 | DEA | Schedules of Controlled Substances: Removal of [18F]FP-CIT from Control DEA-2021-0025 | Schedules of Controlled Substances: Removal of [18F]FP-CIT from Control | Rule | 2022-11-21T05:00:00Z | 2022 | 11 | 2022-11-21T05:00:00Z | 2022-11-21T13:27:57Z | 2022-25212 | 0 | 0 | 09000064854f8554 | ||
| DEA-2020-0015-0013 | DEA | Schedules of Controlled Substances: Placement of Zipeprol in Schedule I DEA-2020-0015 | Schedules of Controlled Substances: Placement of Zipeprol in Schedule I | Rule | 2022-11-21T05:00:00Z | 2022 | 11 | 2022-11-21T05:00:00Z | 2022-11-21T13:29:53Z | 2022-25206 | 0 | 0 | 09000064854f8125 | ||
| DEA-2021-0011-0007 | DEA | Schedules of Controlled Substances: Placement of Amineptine in Schedule I DEA-2021-0011 | Schedules of Controlled Substances: Placement of Amineptine in Schedule I | Rule | 2022-11-17T05:00:00Z | 2022 | 11 | 2022-11-17T05:00:00Z | 2022-11-17T13:05:24Z | 2022-25003 | 0 | 0 | 09000064854bdf02 | ||
| DEA-2020-0027-0006 | DEA | Default Provisions for Hearing Proceedings Relating to the Revocation, Suspension, or Denial of a Registration DEA-2020-0027 | Default Provisions for Hearing Proceedings Relating to the Revocation, Suspension, or Denial of a Registration | Rule | 2022-11-14T05:00:00Z | 2022 | 11 | 2022-11-14T05:00:00Z | 2022-11-14T15:18:19Z | 2022-24425 | 0 | 0 | 09000064854aab24 | ||
| DEA-2022-0134-0001 | DEA | Specific Listing for 1-boc-4-AP, a Currently Controlled List I Chemical (DEA1046) DEA-2022-0134 | Specific Listing for 1-boc-4-AP, a Currently Controlled List I Chemical | Rule | 2022-11-09T05:00:00Z | 2022 | 11 | 2022-11-09T05:00:00Z | 2022-11-09T16:35:58Z | 2022-24155 | 0 | 0 | 090000648549d59a | ||
| DEA-2022-0051-0002 | DEA | Schedules of Controlled Substances: Placement of Ganaxolone in Schedule V DEA-2022-0051 | Schedules of Controlled Substances: Placement of Ganaxolone in Schedule V | Rule | 2022-11-09T05:00:00Z | 2022 | 11 | 2022-11-09T05:00:00Z | 2022-11-09T16:24:54Z | 2022-24157 | 0 | 0 | 090000648549cc67 | ||
| DEA-2022-0133-0001 | DEA | Technical Correction to Regulation Regarding Registration Exception for Officials DEA-2022-0133 | Regulation Regarding Registration Exception for Officials; Technical Correction | Rule | 2022-11-07T05:00:00Z | 2022 | 11 | 2022-11-07T05:00:00Z | 2022-11-07T14:10:14Z | 2022-24140 | 0 | 0 | 0900006485492c7f | ||
| DEA-2022-0025-0006 | DEA | Schedules of Controlled Substances: Placement of Daridorexant in Schedule IV DEA-2022-0025 | Schedules of Controlled Substances: Placement of Daridorexant in Schedule IV | Rule | 2022-09-30T04:00:00Z | 2022 | 9 | 2022-09-30T04:00:00Z | 2022-09-30T12:20:37Z | 2022-21253 | 0 | 0 | 0900006485389e23 | ||
| DEA-2021-0010-0011 | DEA | Schedules of Controlled Substances: Placement of Serdexmethylphenidate in Schedule IV DEA-2021-0010 | Schedules of Controlled Substances: Placement of Serdexmethylphenidate in Schedule IV | Rule | 2022-06-24T04:00:00Z | 2022 | 6 | 2022-06-24T04:00:00Z | 2022-06-24T12:22:19Z | 2022-13538 | 0 | 0 | 090000648518b8dd | ||
| DEA-2021-0030-0005 | DEA | Schedules of Controlled Substances: Placement of Methoxetamine in Schedule I DEA-2021-0030 | Schedules of Controlled Substances: Placement of Methoxetamine (MXE) in Schedule I | Rule | 2022-06-06T04:00:00Z | 2022 | 6 | 2022-06-06T04:00:00Z | 2022-06-06T13:54:29Z | 2022-11933 | 0 | 0 | 0900006485141202 | ||
| DEA-2022-0050-0001 | DEA | Schedules of Controlled Substances: Placement of N-Ethylhexedrone, alpha-Pyrrolidinohexanophenone, 4-Methyl-alpha-ethylaminopentiophenone, 4′-Methyl-alpha-pyrrolidinohexiophenone, alpha-Pyrrolidinoheptaphenone, and 4′-Chloro-alpha-pyrrolidinovalerophenone in Schedule I DEA-2022-0050 | Schedules of Controlled Substances: Placement of N-Ethylhexedrone, alpha-Pyrrolidinohexanophenone, 4-Methyl-alpha-ethylaminopentiophenone, 4′-Methyl-alpha-pyrrolidinohexiophenone, alpha-Pyrrolidinoheptaphenone, and 4′-Chloro-alpha-pyrrolidinovalerophenone in Schedule I | Rule | 2022-06-01T04:00:00Z | 2022 | 6 | 2022-06-01T04:00:00Z | 2022-06-01T16:54:35Z | 2022-11740 | 0 | 0 | 090000648511e3a3 | ||
| DEA-2022-0051-0001 | DEA | Schedules of Controlled Substances: Placement of Ganaxolone in Schedule V DEA-2022-0051 | Schedules of Controlled Substances: Placement of Ganaxolone in Schedule V | Rule | 2022-06-01T04:00:00Z | 2022 | 6 | 2022-06-01T04:00:00Z | 2022-07-02T03:59:59Z | 2022-06-01T16:56:42Z | 2022-11735 | 0 | 0 | 090000648511e3a9 | |
| DEA-2021-0031-0004 | DEA | Schedules of Controlled Substances: Temporary Placement of Butonitazene, Etodesnitazene, Flunitazene, Metodesnitazene, Metonitazene, N-pyrrolidino etonitazene, and Protonitazene in Schedule I DEA-2021-0031 | Schedules of Controlled Substances: Temporary Placement of Butonitazene, Etodesnitazene, Flunitazene, Metodesnitazene, Metonitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I | Rule | 2022-04-12T04:00:00Z | 2022 | 4 | 2022-04-12T04:00:00Z | 2022-04-12T12:55:17Z | 2022-07640 | 0 | 0 | 090000648500fd5c | ||
| DEA-2021-0005-0006 | DEA | Amending Regulations to Require Online Submission of Applications for and Renewals of DEA Registration DEA-2021-0005 | Requiring Online Submission of Applications for and Renewals of DEA Registration | Rule | 2022-04-11T04:00:00Z | 2022 | 4 | 2022-04-11T04:00:00Z | 2022-04-11T12:29:28Z | 2022-07570 | 0 | 0 | 090000648500abee | ||
| DEA-2019-0002-0010 | DEA | Schedules of Controlled Substances: Placement of 5F-EDMBPINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA, and FUB-144 in Schedule I DEA-2019-0002 | Schedules of Controlled Substances: Placement of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA, and FUB-144 in Schedule I | Rule | 2022-04-07T04:00:00Z | 2022 | 4 | 2022-04-07T04:00:00Z | 2022-04-07T15:06:01Z | 2022-07320 | 0 | 0 | 0900006484fff3b7 | ||
| DEA-2022-0025-0001 | DEA | Schedules of Controlled Substances: Placement of Daridorexant in Schedule IV DEA-2022-0025 | Schedules of Controlled Substances: Placement of Daridorexant in Schedule IV | Rule | 2022-04-07T04:00:00Z | 2022 | 4 | 2022-04-07T04:00:00Z | 2022-05-10T03:59:59Z | 2022-05-03T13:22:43Z | 2022-07322 | 0 | 0 | 0900006484fff3ba | |
| DEA-2021-0009-0002 | DEA | MAPA - Designation as List I Chemical: Methyl alpha-phenylacetoacetate, a Precursor Chemical Used in the Illicit Manufacture of Phenylacetone, Methamphetamine, and Amphetamine DEA-2021-0009 | Designation as a List I Chemical: Methyl alpha-phenylacetoacetate, a Precursor Chemical Used in the Illicit Manufacture of Phenylacetone, Methamphetamine, and Amphetamine | Rule | 2021-11-18T05:00:00Z | 2021 | 11 | 2021-11-18T05:00:00Z | 2021-11-18T17:15:49Z | 2021-24952 | 0 | 0 | 0900006484e5f385 | ||
| DEA-2020-0017-0005 | DEA | Schedules of Controlled Substances: Placement of Isotonitazene in Schedule I DEA-2020-0017 | Schedules of Controlled Substances: Placement of Isotonitazene in Schedule I | Rule | 2021-11-04T04:00:00Z | 2021 | 11 | 2021-11-04T04:00:00Z | 2021-11-04T12:13:37Z | 2021-23848 | 0 | 0 | 0900006484e17dd9 | ||
| DEA-2021-0015-0001 | DEA | Schedules of Controlled Substances: Placement of Lemborexant in Schedule IV DEA-2021-0015 | Schedules of Controlled Substances: Placement of Lemborexant in Schedule IV | Rule | 2021-11-03T04:00:00Z | 2021 | 11 | 2021-11-03T04:00:00Z | 2021-11-05T13:57:18Z | 2021-04183 | 0 | 0 | 0900006484a5c6dd | ||
| DEA-2021-0024-0001 | DEA | Adding Space Force to DEA Regulations DEA-2021-0024 | Addition of the United States Space Force as a Registration Waiver and Registration Fee Exempt Military Entity | Rule | 2021-09-17T04:00:00Z | 2021 | 9 | 2021-09-17T04:00:00Z | 2021-11-01T15:11:02Z | 2021-19984 | 0 | 0 | 0900006484d8c25b | ||
| DEA-2020-0009-0006 | DEA | Schedules of Controlled Substances: Placement of 4,4'-DMAR in Schedule I DEA-2020-0009 | Schedules of Controlled Substances: Placement of 4,4′-DMAR in Schedule I | Rule | 2021-08-12T04:00:00Z | 2021 | 8 | 2021-08-12T04:00:00Z | 2021-08-17T15:00:09Z | 2021-17052 | 0 | 0 | 0900006484c48d9a | ||
| DEA-2020-0036-0001 | DEA | Supplier's Registration Number on the Single-Sheet DEA Form 222 DEA-2020-0036 | Clarification Regarding the Supplier's DEA Registration Number on the Single-Sheet DEA Form 222 | Rule | 2021-07-20T04:00:00Z | 2021 | 7 | 2021-07-20T04:00:00Z | 2021-09-21T03:59:59Z | 2021-08-19T01:00:36Z | 2021-15323 | 0 | 0 | 0900006484c03531 | |
| DEA-2019-0009-0002 | DEA | Schedules of Controlled Substances: Temporary Placement of N-Ethylhexedrone, a-PHP, 4-MEAP, MPHP, PV8, and 4-Chloro-a-PVP in Schedule I DEA-2019-0009 | Schedules of Controlled Substances: Extension of Temporary Placement of N-Ethylhexedrone, alpha-Pyrrolidinohexanophenone, 4-Methyl-alpha-ethylaminopentiophenone, 4′-Methyl-alpha-pyrrolidinohexiophenone, alpha-Pyrrolidinoheptaphenone, and 4′-Chloro-alpha-pyrrolidinovalerophenone in Schedule I of the Controlled Substances Act | Rule | 2021-07-16T04:00:00Z | 2021 | 7 | 2021-07-16T04:00:00Z | 2021-10-29T17:47:11Z | 2021-15113 | 0 | 0 | 0900006484bfbc0b | ||
| DEA-2020-0005-0116 | DEA | Registration Requirements for Narcotic Treatment Programs with Mobile Components DEA-2020-0005 | Registration Requirements for Narcotic Treatment Programs with Mobile Components | Rule | 2021-06-28T04:00:00Z | 2021 | 6 | 2021-06-28T04:00:00Z | 2021-07-28T19:03:18Z | 2021-13519 | 0 | 0 | 0900006484bb969c | ||
| DEA-2021-0023-0001 | DEA | Schedules of Controlled Substances: Placement of para-Methoxymethamphetamine (PMMA) in Schedule I DEA-2021-0023 | Schedules of Controlled Substances: Placement of para-Methoxymethamphetamine (PMMA) in Schedule I | Rule | 2021-06-25T04:00:00Z | 2021 | 6 | 2021-06-25T04:00:00Z | 2021-10-29T13:41:35Z | 2021-13460 | 0 | 0 | 0900006484bb1b28 | ||
| DEA-2021-0022-0001 | DEA | Schedules of Controlled Substances: Specific Listing for 4F-MDMB-BINACA, a Currently Controlled Schedule I Substance DEA-2021-0022 | Schedules of Controlled Substances: Specific Listing for 4F-MDMB-BINACA, a Currently Controlled Schedule I Substance | Rule | 2021-06-22T04:00:00Z | 2021 | 6 | 2021-06-22T04:00:00Z | 2021-10-29T13:38:43Z | 2021-13040 | 0 | 0 | 0900006484b9eb92 | ||
| DEA-2019-0004-0003 | DEA | Schedules of Controlled Substances: Temporary Placement of N-Ethylhexedrone, a-PHP, 4-MEAP, MPHP, PV8, and 4-Chloro-a-PVP in Schedule I DEA-2019-0004 | Schedules of Controlled Substances: Placement of N-Ethylpentylone in Schedule I | Rule | 2021-06-14T04:00:00Z | 2021 | 6 | 2021-06-14T04:00:00Z | 2021-08-18T13:25:42Z | 2021-12261 | 0 | 0 | 0900006484b7a208 | ||
| DEA-2020-0032-0005 | DEA | Schedules of Controlled Substances: Placement of Oliceridine in Schedule II DEA-2020-0032 | Schedules of Controlled Substances: Placement of Oliceridine in Schedule II | Rule | 2021-06-10T04:00:00Z | 2021 | 6 | 2021-06-10T04:00:00Z | 2021-06-14T19:51:45Z | 2021-11981 | 0 | 0 | 0900006484b63b03 | ||
| DEA-2021-0021-0001 | DEA | Schedules of Controlled Substances: Placement of NM2201, 5F-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-CHMICA, and 5F-CUMYL-P7AICA in Schedule I DEA-2021-0021 | Schedules of Controlled Substances: Placement of NM2201, 5F-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-CHMICA, and 5F-CUMYL-P7AICA in Schedule I | Rule | 2021-06-10T04:00:00Z | 2021 | 6 | 2021-06-10T04:00:00Z | 2021-10-29T13:35:32Z | 2021-11974 | 0 | 0 | 0900006484b63b53 | ||
| DEA-2021-0020-0002 | DEA | Designation of 3,4-MDP-2-P methyl glycidate (PMK glycidate), 3,4-MDP-2-P methyl glycidicacid (PMK glycidic acid), and alpha-phenylacetoacetamide (APAA) as List I Chemicals DEA-2021-0020 | Designation of 3,4-MDP-2-P methyl glycidate (PMK glycidate), 3,4-MD-2-P methyl glycidic acid (PMK glycidic acid), and alpha-phenylacetoacetamide (APAA) as List I Chemicals: Correction | Rule | 2021-06-07T04:00:00Z | 2021 | 6 | 2021-06-07T04:00:00Z | 2021-10-29T13:22:51Z | 2021-11836 | 0 | 0 | 0900006484b59277 | ||
| DEA-2020-0028-0007 | DEA | Schedules of Controlled Substances: Placement of Remimazolam in Schedule IV DEA-2020-0028 | Schedules of Controlled Substances: Placement of Remimazolam in Schedule IV | Rule | 2021-06-02T04:00:00Z | 2021 | 6 | 2021-06-02T04:00:00Z | 2021-08-18T13:34:04Z | 2021-11512 | 0 | 0 | 0900006484b4cd8d | ||
| DEA-2020-0003-0010 | DEA | Schedules of Controlled Substances: Placement of Lasmiditan in Schedule V DEA-2020-0003 | Schedules of Controlled Substances: Placement of Lasmiditan in Schedule V | Rule | 2021-05-24T04:00:00Z | 2021 | 5 | 2021-05-24T04:00:00Z | 2021-05-25T15:49:44Z | 2021-10827 | 0 | 0 | 0900006484b2e413 | ||
| DEA-2021-0020-0001 | DEA | Designation of 3,4-MDP-2-P methyl glycidate (PMK glycidate), 3,4-MDP-2-P methyl glycidicacid (PMK glycidic acid), and alpha-phenylacetoacetamide (APAA) as List I Chemicals DEA-2021-0020 | Designation of 3,4-MDP-2-P methyl glycidate (PMK glycidate), 3,4-MDP-2-P methyl glycidicacid (PMK glycidic acid), and alpha-phenylacetoacetamide (APAA) as List I Chemicals | Rule | 2021-05-10T04:00:00Z | 2021 | 5 | 2021-05-10T04:00:00Z | 2021-10-29T13:18:05Z | 2021-09697 | 0 | 0 | 0900006484ae1df4 | ||
| DEA-2021-0010-0001 | DEA | Schedules of Controlled Substances: Placement of Serdexmethylphenidate in Schedule IV DEA-2021-0010 | Schedules of Controlled Substances: Placement of Serdexmethylphenidate in Schedule IV | Rule | 2021-05-07T04:00:00Z | 2021 | 5 | 2021-05-07T04:00:00Z | 2021-06-08T03:59:59Z | 2021-06-03T01:00:21Z | 2021-09738 | 0 | 0 | 0900006484ad863b | |
| DEA-2021-0019-0001 | DEA | Schedules of Controlled Substances: Placement of Four Specific Fentanyl-Related Substances in Schedule I DEA-2021-0019 | Schedules of Controlled Substances: Placement of Four Specific Fentanyl-Related Substances in Schedule I | Rule | 2021-05-04T04:00:00Z | 2021 | 5 | 2021-05-04T04:00:00Z | 2021-10-29T13:14:00Z | 2021-09402 | 0 | 0 | 0900006484aca7bd | ||
| DEA-2021-0018-0001 | DEA | Schedules of Controlled Substances: Placement of 10 Specific Fentanyl-Related Substances in Schedule I DEA-2021-0018 | Schedules of Controlled Substances: Placement of 10 Specific Fentanyl-Related Substances in Schedule I | Rule | 2021-04-27T04:00:00Z | 2021 | 4 | 2021-04-27T04:00:00Z | 2021-10-29T13:09:29Z | 2021-08720 | 0 | 0 | 0900006484ab8209 | ||
| DEA-2021-0017-0001 | DEA | Schedules of Controlled Substances: Removal of Samidorphan From Control DEA-2021-0017 | Schedules of Controlled Substances: Removal of Samidorphan From Control | Rule | 2021-04-19T04:00:00Z | 2021 | 4 | 2021-04-19T04:00:00Z | 2021-10-29T11:35:21Z | 2021-07884 | 0 | 0 | 0900006484aab9de | ||
| DEA-2019-0002-0009 | DEA | Schedules of Controlled Substances: Placement of 5F-EDMBPINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA, and FUB-144 in Schedule I DEA-2019-0002 | Schedules of Controlled Substances: Extension of Temporary Placement of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA and FUB-144 in Schedule I of the Controlled Substances Act | Rule | 2021-03-31T04:00:00Z | 2021 | 3 | 2021-03-31T04:00:00Z | 2021-05-17T13:12:19Z | 2021-06555 | 0 | 0 | 0900006484a91bd6 | ||
| DEA-2021-0016-0001 | DEA | Schedules of Controlled Substances: Removal of Samidorphan From Control DEA-2021-0016 | Schedules of Controlled Substances: Placement of cyclopentyl fentanyl, isobutyryl fentanyl, para-chloroisobutyryl fentanyl, para-methoxybutyryl fentanyl, and valeryl fentanyl in Schedule I; Correction | Rule | 2021-03-31T04:00:00Z | 2021 | 3 | 2021-03-31T04:00:00Z | 2021-10-28T17:54:17Z | 2021-06596 | 0 | 0 | 0900006484a91c1f | ||
| DEA-2020-0038-0004 | DEA | Schedules of Controlled Substances: Placement of Brorphine in Schedule I DEA-2020-0038 | Schedules of Controlled Substances: Temporary Placement of Brorphine in Schedule I | Rule | 2021-03-01T05:00:00Z | 2021 | 3 | 2021-03-01T05:00:00Z | 2023-03-02T13:25:25Z | 2021-04242 | 0 | 0 | 0900006484a5717c |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE documents (
id TEXT PRIMARY KEY,
agency_id TEXT,
docket_id TEXT REFERENCES dockets(id),
title TEXT,
document_type TEXT,
subtype TEXT,
posted_date TEXT,
posted_year INTEGER,
posted_month INTEGER,
comment_start_date TEXT,
comment_end_date TEXT,
last_modified TEXT,
fr_doc_num TEXT,
open_for_comment INTEGER,
withdrawn INTEGER,
object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date) WHERE comment_end_date IS NOT NULL AND withdrawn = 0;